OnKure Therapeutics (NASDAQ:OKUR) Stock Rating Lowered by JonesTrading

OnKure Therapeutics (NASDAQ:OKUR) was downgraded by research analysts at JonesTrading from a “strong-buy” rating to a “hold” rating in a research note issued on Thursday,Zacks.com reports.

Several other brokerages also recently weighed in on OKUR. Weiss Ratings upgraded shares of OnKure Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, April 24th. HC Wainwright reduced their price target on shares of OnKure Therapeutics from $34.00 to $27.00 and set a “buy” rating on the stock in a research report on Monday, March 16th. Finally, Wall Street Zen upgraded shares of OnKure Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, March 14th. One research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, OnKure Therapeutics presently has a consensus rating of “Hold” and an average price target of $27.00.

OnKure Therapeutics Stock Performance

Shares of OKUR stock opened at $3.96 on Thursday. OnKure Therapeutics has a one year low of $1.70 and a one year high of $5.38. The company has a 50 day moving average price of $4.10 and a 200 day moving average price of $3.32. The firm has a market capitalization of $54.13 million, a price-to-earnings ratio of -0.91 and a beta of 0.36.

OnKure Therapeutics (NASDAQ:OKUR) last issued its quarterly earnings results on Tuesday, May 5th. The company reported ($1.11) EPS for the quarter, missing the consensus estimate of ($0.74) by ($0.37). As a group, equities analysts forecast that OnKure Therapeutics will post -2.74 EPS for the current fiscal year.

Hedge Funds Weigh In On OnKure Therapeutics

Large investors have recently bought and sold shares of the stock. XTX Topco Ltd acquired a new position in OnKure Therapeutics during the 2nd quarter valued at about $25,000. Jane Street Group LLC bought a new position in shares of OnKure Therapeutics during the 4th quarter valued at about $56,000. Hsbc Holdings PLC bought a new position in shares of OnKure Therapeutics during the 4th quarter valued at about $58,000. Rangeley Capital LLC bought a new position in shares of OnKure Therapeutics during the 2nd quarter valued at about $71,000. Finally, Barclays PLC boosted its position in shares of OnKure Therapeutics by 4,286.8% during the 4th quarter. Barclays PLC now owns 27,242 shares of the company’s stock valued at $79,000 after purchasing an additional 26,621 shares in the last quarter. Institutional investors and hedge funds own 90.98% of the company’s stock.

OnKure Therapeutics Company Profile

OnKure Therapeutics, Inc (NASDAQ: OKUR) is a clinical-stage biopharmaceutical company focused on the development of novel therapies for oncology and autoimmune diseases. Headquartered in Westlake Village, California, OnKure is advancing small molecule drug candidates designed to modulate key signaling pathways implicated in cancer cell growth and immune system function.

The company’s lead oncology asset, OKI-179, is an orally available histone deacetylase (HDAC) inhibitor being evaluated in Phase I and Phase II clinical studies for a range of solid tumors.